Myogenic transcription is repressed in myoblasts by serum-activated cyclin-dependent kinases, such as cdk2 and cdk4. Serum withdrawal promotes muscle-speci®c gene expression at least in part by down-regulating the activity of these cdks. Unlike the other cdks, cdk9 is not serum-or cell cycle-regulated and is instead involved in the regulation of transcriptional elongation by phosphorylating the carboxyl-terminal domain (CTD) of RNA polymerase II. While ectopic expression of cdk2 together with its regulatory subunits (cyclins E and A) inhibits myogenic transcription, overproduction of cdk9 and its associated cyclin (cyclin T2a) strengthens MyoD-dependent transcription and stimulates myogenic dierentiation in both MyoD-converted ®broblasts and C2C12 muscle cells. Conversely, inhibition of cdk9 activity by a dominant negative form (cdk9-dn) represses the myogenic program. Cdk9, cyclinT2 and MyoD can be detected in a multimeric complex in C2C12 cells, with the minimal cdk9-binding region of MyoD mapping within 101 ± 161 aa of the bHLH region. Finally, cdk9 can phosphorylate MyoD in vitro, suggesting the possibility that cdk9/cycT2a regulation of muscle dierentiation includes the direct enzymatic activity of the kinase on MyoD.
Introduction
Cyclin-dependent kinase 9 (cdk9) is a cdk1-related serine/threonine kinase, previously named PITALRE (Grana et al., 1994) , which is widely expressed in human and murine tissues with high levels found in terminally dierentiated cells (De Luca et al., 1997a; Bagella et al., 1998 Bagella et al., , 2000 . The regulatory units of cdk9 are the T family cyclins (T1, T2a and T2b) and cyclin K (Fu et al., 1999) . Cyclin T1 (cycT1) and cyclin T2 (cycT2) mRNAs are expressed widely in adult human tissues with higher levels in muscle, the spleen, thymus, testes, ovaries and in peripheral blood lymphocytes. In HeLa nuclear extracts, roughly 80% of cdk9 is complexed with cycT1 and 10% with cycT2a and cycT2b Peng et al., 1998) . Cyclin K is ubiquitously expressed in adult mouse and human tissue, but is most abundant in developing germ cells of the adult testes and ovaries (Edwards et al., 1998) . The elevated levels of cdk9 and its regulatory subunits (cyclins T1 and T2) in terminally dierentiated cells, together with the fact that cdk9/cyclinT complexes are not cell cycle-regulated, distinguish cdk9 from the other cdks (MacLachlan et al., 1995; De Falco and Giordano, 1998) . Moreover, unlike the other cdks, which regulate cell cycle progression and phosphorylate histone H1, cdk9 fails to phosphorylate H1. It is instead implicated in the regulation of transcriptional elongation via phosphorylation of the carboxyl-terminal domain (CTD) of RNA polymerase II (Grana et al., 1994; Dahmus, 1996; Marshall et al., 1996; Zhu et al., 1997) . A kinase activity corresponding to cdk9 has been detected in the HIV Tat-associated kinase (TAK) complex, where cdk9 is required for Tat-dependent stimulation of transcriptional elongation (Yang et al., 1996; Mancebo et al., 1997) . CycT1 was the ®rst cyclin discovered to associate with cdk9 thereby forming a complex that interacts with HIV-1-Tat protein in the TAK complex . Human cycT1 markedly stimulates Tat activation, while cycT2a and T2b fail to form a complex with Tat bound to the transactivation response RNA element (TAR) (Kwak et al., 1999; Wimmer et al., 1999) . These data indicate functional dierences between cycT1 and cycT2. In addition, unlike cyclin T1 and cyclin T2, the targeted recruitment of cyclin K to promoter DNA does not stimulate transcription in vivo (Napolitano et al., 2000) .
In human cells, cdk9 complexes are required for transcription of major histocompatibility class II (MHCII) genes (Kanazawa et al., 2000) and, in Drosophila cells, are involved in the regulation of many, but not all, genes (Lis et al., 2000) . These data suggest that cdk9/cyclinT complexes are not a general basal factor, but depending on cell types, they could represent promoter-speci®c transcriptional elongation complexes. This hypothesis is con®rmed by the fact that TAK/P-TEFb activation exerts a dierent function in the dierentiation program of lymphocytes compared to that of monocytes/macrophages (Foskett et al., 2001) . Activation of cdk9/cyclin T1 in peripheral blood lymphocytes (PBLs) involves an increase in mRNA and the levels of both proteins (Garriga et al., 1998) ; conversely, phorbol myristate acetate (PMA)-induced dierentiation of promonocytic cells involves only cyclin T1 protein levels through posttranscriptional modi®cation (Herrmann et al., 1998) . In monocyte dierentiation, cdk9 has a clear and important role; in fact, the overexpression of cdk9dn in U937 cells renders them sensitive to apoptosis after PMA induction of the dierentiation program (Foskett et al., 2001) .
The dierences between cdk9 and those cdks involved in the regulation of the cell cycle may also re¯ect a dierent function during terminal dierentiation of muscle cells. In this context, the induction of myocyte dierentiation upon serum withdrawal is accompanied by the down-regulation of cyclins D1, E and A and the up-regulation of several cdk inhibitors, which lock the cyclin-cdk complexes in an inactive form. This allows exit from the cell cycle and the expression of musclespeci®c genes (Walsh and Perlman, 1997) . Transcription of genes that contribute to the phenotypic and biochemical identity of dierentiated muscle cells is activated by myogenic bHLH transcription factors, including MyoD, Myf5, myogenin and MRF4 (Wei and Paterson, 2001 ). These proteins operate by heterodimerizing with the E2A gene products via the HLH domain and by binding to certain recognition sites (Ebox) in the regulatory regions of muscle-speci®c genes (Murre et al., 1989; Lassar et al., 1991; Weintraub et al., 1991) . Overexpression of cyclin/cdks has been reported to inhibit the activity of MyoD and prevent myogenic dierentiation by dierent modalities (Puri and Sartorelli, 2000) . For instance, overproduction of cyclins E and A, together with their associated kinase, cdk2, impinges on MyoD function by virtue of their ability to phosphorylate pRb (Skapek et al., 1996; Guo and Walsh, 1997) , an essential co-factor for MyoDdependent transcription (Gu et al., 1993; . In addition, cdk2 (and the cyclin B-associated kinase, cdk1) can inactivate MyoD function by phosphorylating serine 200, thereby triggering MyoD degradation (Song et al., 1998; Kitzmann et al., 1999) . Finally, cyclin D1 overexpression inhibits myogenic dierentiation by promoting the nuclear accumulation of cdk4, which in turn binds the C-terminus of MyoD and prevents MyoD DNA binding and activation of myogenic transcription (Zhang et al., 1999a,b) . In this study we show that, unlike other cyclin/cdk complexes, cdk9/cycT2a levels and activity are not down-regulated during muscle dierentiation. Overproduction of cdk9/ cycT2a enhances MyoD function and promotes myogenic dierentiation, while inhibition of cdk9 kinase activity by a dominant negative form (cdk9dn) prevents the activation of the myogenic program. The Nterminal region of cdk9 directly interacts with the bHLH region of MyoD, allowing the formation of a complex also containing cycT2a. Finally, our data suggest that cdk9-mediated phosphorylation of MyoD could be one of the mechanisms responsible for cdk9-dependent stimulation of myogenic transcription.
Results
The cdk9/cycT2a complex enhances the transcriptional activity of MyoD
To establish a functional dierence between cdk9 and cell cycle-regulated cdks, we ®rst compared the eect of overproduction of cdk2, along with its regulatory subunits (cyclins E and A) to that of cdk9/cycT on MyoD-dependent transcription. The E-box-speci®c 4RE-luciferase reporter (4RE-luc) was transiently transfected into NIH3T3 cells and the in¯uence of either cdk2/cyclins E and A or cdk9, cdk9dn and Ttype cyclins on the transactivation potential of MyoD was assayed after 48 h in dierentiation medium (DM) (2% horse serum DMEM) (Figure 1a ). Co-transfection of either cyclin E-cdk2 or cyclin A-cdk2 reduced the activation of 4RE by MyoD (Figure 1a ). Cdk9 and cdk9dn alone and with cycT1, cycT2a and cycT2b did not aect the basal transcriptional level of the reporter (Figure 1a ). When co-transfected with MyoD, only the addition of cdk9 and cycT2a enhanced MyoDdependent transcription. Conversely, ectopic expression of a kinase-defective form of cdk9 with the property of a dominant negative (cdk9dn) inhibited MyoD transactivation ( Figure 1a) . By using the muscle creatine kinase luciferase (MCK-luc) reporter, we con®rmed the ability of the combination of cdk9 and cycT2a to enhance MyoD-dependent transcription (Figure 1b) . Again, we found that the dominant negative form of the kinase strongly down-regulated MyoD-dependent myogenic transcription (Figure 1b) . Similar results were also observed using a Gal4MyoD fusion protein whose activity was scored by a Gal4-luc reporter (Figure 1c ). In this assay the transcriptional activity of MyoD is not in¯uenced by changes in DNA binding, indicating that cdk9/cycT2a can stimulate MyoD function without altering its binding to the DNA. Gal4-MyoD was not transactivated by cdk9 alone or by cdk9 with cycT1 or cycT2b; however, co-transfection with cdk9 and cycT2a stimulated Gal4-MyoD activity (Figure 1c ). Also in this setting, we found that the expression of cdk9dn down-regulates the activity of MyoD (Figure 1c) . To test the speci®city of the eect of cdk9/cycT2a on MyoD-mediated transcription, we used Gal4-VP16 and the Gal4-luc reporter. The same combination as indicated in Figure 1c was used and we found that all T family cyclins were able to cooperate with cdk9 to activate transcription (data not shown). The results obtained are in accordance with data previously reported . Next, we performed a myogenic conversion assay using the ability of MyoD to convert dierent cell lines into multinucleated myotubes. 10T1/2 cells were transiently transfected with a reporter expressing b-galactosidase localized in the nucleus, under the control of the myosin light chain promoter (MLC-b-gal), which is transactivated during myogenic dierentiation (McGrew et al., 1996) . These cells were co-transfected with MyoD, cdk9, cdk9dn and cycT2a expression vectors in various combinations. As shown in Figure  1d ,e, cdk9/cycT2a was capable of enhancing MyoDmediated conversion, while cdk9/cycT2b and cdk9/ cycT1 do not (data not shown). Cdk9/cycT2a alone Oncogene Physical and functional interactions between MyoD and cdk9 C Simone et al was unable to convert 10T1/2 cells into myotubes and to transactivate the MLC reporter, which gives only background levels. Finally, cdk9dn/cycT2a inhibited MyoD-mediated conversion of ®broblasts into multinucleated myotubes.
The kinase activity of cdk9 is necessary during muscle differentiation
Based on the results reported in the preceding section, we hypothesized that the kinase activity of cdk9 could have a relevant function during myogenic dierentiation. We addressed the functional impact of cdk9 on C2C12 dierentiation by establishing C2C12 cell clones overexpressing EGFP alone, EGFP-cdk9 and EGFPcdk9dn (referred to as C2-EGFP, C2-EGFP-cdk9 and C2-EGFP-cdk9dn, respectively). The impaired activity of endogenous cdk9 in C2C12 cells ectopically expressing cdk9dn (the C2-EGFP-cdk9dn clones) was veri®ed by kinase assay (see Figure 5b ). The cells were analysed during dierentiation by monitoring three dierent markers of dierentiation: (1) morphology, (2) expression of muscle-speci®c genes and (3) transcriptional activity of a myogenic reporter.
The cells were plated onto microscope slides and induced to dierentiate for 5 days. We found striking
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C Simone et al dierences between these three cell lines. The C2-EGFP-cdk9 cells started to form multinucleated myotubes earlier than the mock control (C2-EGFP) ( Figure 2a , middle panels), whereas the C2-EGFPcdk9dn cells failed to form myotubes at all ( Figure 2a , right panels). The C2-EGFP-cdk9dn cells, when induced with DM, were unable to undergo the dierentiation program and became sensitive to cell death (data not shown), as was demonstrated for U937 promonocytic cells after PMA induction (Foskett et al., 2001) . To con®rm the morphological data, we analysed the expression of early and late dierentiation markers by immunoblot analysis. Myogenin was considered as an early marker and MHC as a late marker for muscle dierentiation. Extracts from the three stable cell lines cultured in growth medium (GM) or after 6, 12, 24 and 36 h in DM were collected and examined for the expression of myogenin and MHC. The C2-EGFPcdk9 cells expressed more abundant levels of myogenin than the control C2-EGFP cells (Figure 2b ), while myogenin was undetectable in the C2-EGFP cdk9dn cells at all points examined (Figure 2b ). In a similar experiment we collected cells both in GM and at dierent time points during 5 days of culture in DM (Figure 2c ). The cell extracts were probed with an anti-MHC antibody. MHC levels were signi®cantly higher in C2-EGFP-cdk9 cells than C2-EGFP cells ( Figure  2c ). Again, overexpression of cdk9dn inhibited the expression of MHC during dierentiation (Figure 2c ). In order to further evaluate the impact of cdk9 on the myogenic program, we transfected the three stable cell lines with a muscle-speci®c luciferase reporter to evaluate its activity during muscle dierentiation. We utilized the muscle creatine kinase promoter fused to the luciferase gene (MCK-luc). The activation of MCK-luc was higher in C2-EGFP-cdk9 cells than C2-EGFP cells, while the C2-EGFP-cdk9dn cells always maintained the basal level (Figure 2d ). These sets of experiments strongly support the role of cdk9 in promoting muscle dierentiation.
The N-terminus of cdk9 directly interacts in vitro with the bHLH domain of MyoD
The myogenic program in C2C12 is initiated by the activation of pre-existing myogenic regulatory proteins, After transfection, the cells were placed in DM and luciferase activity was measured after 0, 24, 48 and 72 h. All the experiments were repeated at least three times. The transfections were performed in triplicate and normalized for b-gal activity such as MyoD and Myf5. These bHLH factors are latent in myoblasts and can be activated by placing the cells in a serum-deprived medium. Thus, if cdk9 has a role in the induction of myogenic dierentiation by serum withdrawal, MyoD could be one possible target of this kinase. Previous studies have reported the inhibition of MyoD by cdks, either by physical interaction (as in the case of cdk4) (Zhang et al., 1999a) , or by direct phosphorylation (as in the case of cdk2 and cdk1) (Kitzmann et al., 1999; Song et al., 1998) . Thus, interaction with cell cycle-regulated cdks can provide an inhibitory constraint for MyoD in myoblasts. In a similar fashion, we reasoned that the positive eect of cdk9 on myogenic transcription could be mediated by a physical interaction with MyoD. To test whether a direct physical interaction occurs between cdk9 and MyoD, we ®rst investigated if the two proteins could interact in vitro. To this purpose, in vitro translated 35 S labeled cdk9, cdk9dn and three deletion mutants, cdk9 (129 ± 372), cdk9 (218 ± 372) and cdk9 (1 ± 195) (Figure 3a) , were tested for their ability to interact with GST-MyoD in a pull-down assay. GST alone was used as a negative control. An interaction was detected with the full-length cdk9, with cdk9dn and with cdk9 (1 ± 195) (Figure 3c,d) . The same experiment was performed using wild-type MyoD and three deletion mutants of in vitro translated MyoD. MyoD (1 ± 100) lacks the bHLH domain and the C- MyoD (162 ± 318) lacks the N-terminus and the bHLH domain and MyoD (1 ± 185) lacks most of the C-terminus (Figure 3b ). Full-length MyoD interacted with GST-cdk9, but not with GST alone used as a negative control (Figure 3c ). The binding also occurred with MyoD (1 ± 185), whereas the interaction was undetectable with the other two mutants ( Figure  3e ). These data indicate that the regions mediating the binding between cdk9 and MyoD encompass the bHLH domain of MyoD (101 ± 161 aa) and the Nterminus (1 ± 128 aa) of cdk9 (see Figure 3a) . To further de®ne whether the two proteins interact directly, or if an unknown protein present in the reticulocyte lysate mediates the binding, we analysed the in vitro interaction between bacterially puri®ed GST-cdk9 and dierent mutants of histidine-tagged MyoD (His-MyoD). Full-length His-MyoD and dierent His-MyoD deletions (MyoD-C-ter expressing the carboxyl-terminal domain, MyoD-bHLH the bHLH domain and MyoD-N-ter the amino terminal domain) were tested for their ability to bind to cdk9. In a pulldown assay followed by immunoblot with anti-cdk9, only full-length MyoD and the bHLH fragment were able to interact with the GST-cdk9 (Figure 3f ). These data con®rm that cdk9 directly interacts with the bHLH domain of MyoD.
Using an independent approach we set out to investigate whether the binding between MyoD and cdk9 allows for the simultaneous recruitment of cdk9 and the cdk9-associated cycT2a, thus making the formation of a multimeric complex possible. We performed an in vitro experiment using His-MyoD and an in vitro translated form of 35 S-cdk9 and -cycT2a. In a pull-down assay in which His-MyoD was precipitated, cycT2a and cdk9 were both recruited by MyoD (Figure 3g , lanes 5 and 6). The transcription factor pulled down the two proteins together with the same eciency (Figure 3g, lane 7) . These data indicate that, at least in vitro, MyoD is able to independently bind cdk9 and cycT2a, and that the mutual binding between the three proteins allows the formation of a multimeric complex.
Cdk9, MyoD and cycT2 form a multimeric complex in vivo
To verify that the interaction described above was present in vivo, we performed immunoprecipitations (Ips) from proliferating C2C12 myoblasts growing in GM or induced to dierentiate in DM. Based on the fact that MyoD is activated in the early phase of the dierentiation program, we collected logarithmically growing cells and cells after 24 h in DM. Whole cell extracts were immunoprecipitated with anti-cdk9 antibody and subjected to immunoblotting with antiMyoD antibody. As presented in Figure 4 , MyoD and cdk9 could be co-immunoprecipitated with a-cdk9 antibody in GM as well as early DM, while neither cdk9 nor MyoD was detected in the Ip with preimmune rabbit serum. Further analysis of the a-cdk9 antibody immunoprecipitates revealed the presence of three types of T cyclins: T1, T2a and T2b (Figure 4a ). The cycT2-speci®c serum used in the immunoblot was raised against human cyclin T2. In preliminary experiments, we tested the ability of anti-human cyclin T2 to cross-react with mouse cycT2. The serum detects a similar pattern of two bands corresponding to the two isoforms cycT2a and cycT2b (approximatively 80 and 88 kD, respectively) in mouse and human extracts. In an additional experiment, anti-MyoD antibody was able to co-immunoprecipitate cdk9 and cycT2, but not cycT1, con®rming the transcriptional data presented in Figure 1 (Figure 4b) .
Because cdk9/cycT2a was the only activator of MyoD in functional assays (Figure 1a,b) , since cycT2a, alone and in combination with cdk9, interacted with MyoD in vitro (Figure 3g) , and, ®nally, to con®rm the data presented in Figure 4b , we performed immunoprecipitations (Ips) from proliferating C2C12 cells and dierentiated C2C12 cells by using anti-cycT2 antibody. The associated proteins were detected by Western blot with anti-MyoD, anti-cdk9, anti-cycT2 and anti-cycT1 antibodies. As presented in Figure 4c , MyoD, cycT2 and cdk9 could be co-immunoprecipitated with anti-cycT2 antibody in GM as well as early DM, while neither cycT2 nor cdk9 and MyoD was detected in the Ip with pre-immune rabbit serum. The immunoblot analysis of the anti-cycT2 antibody Ip also revealed the absence of cycT1 as previously described .
Cdk9 phosphorylates MyoD and its kinase activity peaks at 24 h of muscle differentiation
The involvement of cdk9-speci®c kinase activity in myogenesis and its association with MyoD prompted us to analyse the possibility that MyoD might be a substrate for cdk9. Kinase assays were performed using immunoprecipitated cdk9 complexes of C2C12 cells. Puri®ed His-MyoD was used as a substrate. As shown in Figure 5a , whole cell extracts from C2C12 myoblasts were incubated with antibodies against cdk2 and cdk5, which were used as the positive and negative control, respectively (Kitzmann et al., 1999) , and against cdk9. His-MyoD was eciently phosphorylated by cdk2, but not by cdk5, as previously reported (Kitzmann et al., 1999) . Immunoprecipitated cdk9 could phosphorylate His-MyoD as eciently as cdk2 (Figure 5a, lanes 3 and 4) , indicating that MyoD is a good in vitro substrate for cdk9. To con®rm that MyoD phosphorylation depended on cdk9 and not another protein present in the complex, we performed an immunoprecipitation with anti-cdk9 from C2-EGFP and C2-EGFP-cdk9dn cell extracts and a kinase assay with His-MyoD as a substrate. No signi®cant dierence from the negative control (Ip anti-NRS) was observed, con®rming that the in vitro phosphorylation of MyoD depended only on cdk9 kinase activity (Figure 5b) . A study of the phosphorylation of MyoD during myogenesis showed that the activity of cdk9 towards MyoD peaked at 24 h in DM (Figure 5c ). This fact is noteworthy since it raises the possibility that the phosphorylation of MyoD by cdk9 is a positive signal that stimulates muscle-speci®c gene expression during the early phase of dierentiation.
Cdk9 phosphorylation of MyoD does not influence MyoD stability in vivo
Cdk1 and cdk2 are able to phosphorylate MyoD on Ser200, which allows MyoD degradation via the ubiquitin-proteosome pathway (Kitzmann et al., 1999) . In order to understand if cdk9 could interfere with the stability of MyoD, half-life studies were performed. Whole cell extracts were subjected to immunoblot analysis 0, 15, 30, 45, 60, 90 and 120 min after protein synthesis was inhibited by cycloexamide addition. The MyoD levels were evaluated in the three stable C2C12 cell lines (C2-EGFP, C2-EGFP-cdk9 and C2-EGFP-cdk9dn). No signi®cant dierences were observed (data not shown). Similar experiments were performed using extracts of transiently transfected NIH3T3 and 10T1/2 cells. Neither ectopic expression of cdk9 nor cdk9dn had a signi®cant impact on exogenous MyoD (data not shown). These data imply that unlike cdk1 and cdk2, cdk9 does not interfere with the stability of MyoD and suggest that serine residues other than serine 200 can be phosphorylated by cdk9.
Discussion
In this study we have shown that cdk9, in association with cyclinT2a, plays an important role in the activation of the myogenic program. With the exception of cdk5, the other cdks have been reported to be functionally down-regulated during muscle dierentiation and their ectopic activation impedes the induction of muscle-speci®c transcription (Walsh and Perlman, 1997) . Unlike these cdks, cdk9 and its regulatory subunit cyclin T2a are not inactivated during myotube formation and are instead implicated in the activation of MyoD. The formation of a multimeric complex, containing cdk9/cycT2a and MyoD is detectable in muscle cells both prior to and during activation of the dierentiation program. This raises the possibility that this complex can be functionally inactivated in myoblasts by inhibitory signals. Alternatively, or in addition, the complex might be present in myoblasts in a latent form due to Figure 4 Cdk9, cycT2 and MyoD co-immunoprecipitate in C2C12 in GM as well as in DM. (a) C2C12 whole cell extracts were precleared and incubated with anity puri®ed anti-cdk9 and pre-immune serum (NRS) (used as a negative control). After extensive washes, the samples were resuspended in LAEMMLI-Buer, split in two parts and loaded respectively on 6% (upper panel) and 10% (lower panel) acrylamide gel. The associated proteins were detected by immunoblot by using anti-cycT1, anti-cycT2, anti-cdk9 and anti-MyoD antibodies. (b) Under the same conditions as previous experiments Ip with anti-MyoD antibody was blotted with anti-cycT1, anti-cycT2, anti-cdk9 and anti-MyoD antibody. (c) Whole cell extracts were precleared and incubated with anti-cycT2 and the pre-immune serum (NRS) (used as a negative control). The samples were split in two parts and loaded respectively on 6% (upper panel) and 8% (lower panel) gel. The associated proteins were detected by immunoblot with anti-cycT1, anti-cycT2, anticdk9 and anti-MyoD antibodies Physical and functional interactions between MyoD and cdk9 C Simone et al the failure of MyoD to form a productive complex with E2A products and to eciently bind the DNA (Lassar and MuÈ nsterberg, 1994) . In accordance with this possibility, it was necessary to place the cells in DM in order to achieve the functional enhancement of MyoD-dependent transcription by cdk9/cycT2a (Figures 1 and 2) . Nevertheless, we cannot exclude that engagement of cdk9/cycT2a by MyoD might be relevant for other still unknown functions of MyoD in myoblasts. Experiments concerning overexpression indicate that upon induction of muscle dierentiation, cdk9/cycT2a promotes MyoD-dependent transcription and accelerates the myogenic program. Conversely, suppression of cdk9 activity by the overproduction of a dominant negative form of cdk9 impairs MyoD activity and prevents the expression of muscle-speci®c markers. These results identify cdk9 as an essential kinase during the activation of the myogenic program. As previously reported, cdk9 catalytic activity is low in promonocytic cells, according to the monocyte/macrophage homeostasis that implies, after a period of a few days during which they circulate in the blood, they undergo dierentiation or apoptosis (Foskett et al., 2001) . After induction of the dierentiation program, cells in which the cdk9 protein is inactivated cannot continue to dierentiate and they undergo apoptosis. To our knowledge and according to the data present in the literature, the antiapoptotic cdk9 function appears to be due only to a block in the dierentiation program by the cdk9dn protein. Finally, the cells in which cdk9 function is impaired try uselessly to dierentiate, causing a switch toward the apoptosis pathway.
While a general transactivating eect of cdk9 on transcription can be predicted by its function as an RNA polymerase II-activating kinase (Moncebo et al., 1997; Zhu et al., 1997) , the role of cdk9 in modulating promoter-restricted transcription appears to be dependent on the sequence-speci®c factor that recruits cdk9. In fact, unlike MyoD, B-Myb function is suppressed by overproduction of cdk9 (De Falco et al., 2000) . In Figure 5 Cdk9 phosphorylates MyoD in vitro and its kinase activity peaks in the early phase of the dierentiation program. (a) Ips were performed with anti-cdk5, anti-cdk2, anti-cdk9 and with pre-immune serum in growing C2C12. The immunocomplexes were extensively washed, incubated in kinase assay reaction buer with 0.5 mg of dialyzed His-mMyoD and resolved on 10% gel. (b) Ips with anti-cdk9 antibody, and pre-immune rabbit serum, in C2-EGFP and C2-EGFP-cdk9dn, and the kinase assay were performed as previously reported. (c) C2C12 were induced to dierentiate and collected every 24 h. The extracts were immunoprecipitated with anity puri®ed anti-cdk9 and incubated with 0.5 mg of dialyzed HisTag-mMyoD in kinase reaction buer and subjected to autoradiography. The data shown are representative of three independent experiments addition, the cdk9/cyclinT1 complex is able to regulate MHCII genes, but not CD96, CD25 or IL-2 genes (Foskett et al., 2001) , con®rming a promoter-speci®c activity with respect to a general eect on basal transcription. This may re¯ect an opposite function of cdk9/cycT complexes on distinct promoters, resulting in synergistic eects toward a coordinated process, such as muscle dierentiation, which requires both activation and inactivation of a variety of genes. Engagement of cdk9/cycT by muscle-speci®c activators (e.g., MyoD-family members) would result in activation of transcription. Recruitment of the cdk9/cycT complex by proteins such as B-Myb, whose activity counteracts myogenic dierentiation, might prevent the transcription of anti-myogenic genes.
The importance of cdk9 activity in sustaining MyoD-mediated transcription and myogenic dierentiation is underscored by experiments of either cdk9 overexpression or, remarkably, functional inactivation by a cdk9 kinase-defective mutant. In addition, data presented in Figure 5 suggest the possibility that the cdk9/cycT2a complex could phosphorylate MyoD in vivo and that phosphorylation is the key to the cdk9-mediated activation of MyoD during the muscle dierentiation program. Given the importance of cdk interaction, phosphorylation, as well as other posttranslational modi®cations, in regulating MyoD function during the myoblast-to-myotube transition (Puri and Sartorelli, 2000; Wei and Paterson, 2001) , it is likely that cdk9 binding to MyoD plays a critical role in the control of skeletal myogenesis.
How would the recruitment of cdk9/cycT2a (and eventually phosphorylation) augment MyoD transcriptional function? The activation domain of MyoD has been implicated in the recruitment of the co-activator p300 (Sartorelli et al., 1997) , which is required for MyoD-dependent transcription (Yuan et al., 1996; Eckner et al., 1996; Puri et al., 1997a,b) . Thus, it is possible that cdk9-mediated phosphorylation might regulate this interaction. Likewise, recruitment of cdk9 by MyoD can allow the phosphorylation of MyoD-associated acetyl-transferases, such as p300 itself and PCAF, to modulate their own enzymatic activity during myogenic transcription (Puri et al., 1997b; Sartorelli et al., 1999; reviewed in Sartorelli and Puri, 2001) . Additionally, the recruitment of cdk9/ cycT2a by the bHLH region of MyoD can provide a functional link between MyoD and the basal machinery transcription, resulting in the stimulation of transcription elongation through the ability of cdk9 to phosphorylate the CTD of RNA polymerase II (Simone and Giordano, 2001) . In this regard, it is also possible that cdk9 binding with MyoD could modulate the potency of cdk9 in stimulating transcription elongation. The complex regulation of MyoD by a variety of signals and the activating network of muscle regulatory factors during myogenic dierentiation suggest that cdk9 phosphorylation of MyoD could be one of these positive signals. This explanation is supported by the extremely high redundancy of regulation of myogenic transcription in cell culture and in vivo models (Lassar and MuÈ nsterberg, 1994; Molkentin and Olson, 1996) .
In conclusion, this study reveals a role for cdk9, in association with cyclinT2a, in assisting MyoD during the activation of muscle-speci®c transcription. Future studies are awaited to further de®ne the molecular mechanism(s) underlying the myogenic function of cdk9 to verify its biological relevance using in vivo models.
Materials and methods

Cell lines, stable transfections and differentiation assay
Stable C2C12 cells, overexpressing EFGP were generated as EGFP-cdk9 and EGFP-cdk9dn, described elsewhere . The stable mix-clones were selected with G-418 (0.5 mg/ml; Sigma, MO, USA) avoiding con¯uence at any time. C2C12, EGFP-C2C12, EGFP-cdk9-C2C12 and EGFP-cdk9dn-C2C12, NIH3T3 and 10T1/2 cells were grown in DMEM supplemented with 10% FBS, L-glutamine and antibiotics (GM). To induce muscle dierentiation, the cells were cultured in DMEM supplemented with 2% HS, Lglutamine and antibiotics (DM). All cell lines were obtained from ATCC.
Myogenic conversion assay
10T1/2 cells were plated 70% con¯uence in 100 mm dishes, transfected with MyoD in the absence or presence of other cdk/cyclin combinations, as reported in the text, and cultured in DM for 48 h. Cells were ®xed in formaldehyde/ gluteraldehyde and stained for b-gal using the standard procedure.
Plasmids
The constructs pcDNA3-cdk9wt-HATag and pcDNA3-cdk9dn-HATag expressing full-length wild-type cdk9 and its kinase-de®cient counterpart have been previously described (De Falco et al., 2000) . The constructs pcDNA3-cdk9 (D1 ± 129)-HATag, pcDNA3-cdk9 (D1 ± 218)-HATag and pcDNA3-cdk9 (D195 ± 372) have also been described elsewhere (Simone et al., submitted). The plasmids pcDNA3-mMyoD (D101 ± 318), pcDNA3-mMyoD (D186 ± 318) and pcDNA3-mMyoD (D1 ± 161) coding for, respectively, MyoD (1 ± 100), MyoD (1 ± 185) and MyoD (162 ± 318) were constructed by PCR. The ampli®ed products were subcloned in the BamHI site of the pcDNA3 vector (Invitrogen). The correct sequences of all these constructs were con®rmed by sequencing using the Applied Biosystem model 373A DNA sequencer. GST-cdk9 (De Falco et al., 2000) , the constructs expressing HA-cyclin T1, HA-cyclin T2a, HA-cyclin T2b , MCKluciferase, 4RE-luciferase, Gal4-luciferase and Gal4-MyoD-wt have been described previously. His-MyoD fusion proteins (wt and the mutants) have been previously described (Sartorelli et al., 1999) .
In vitro binding
The TNT coupled reticulocyte kit was used for in vitro translation (Promega, WI, USA), according to the manufacturer's instructions. All the samples were labeled using 35 SMethionine (Amersham, IL, USA). The labeled samples were Physical and functional interactions between MyoD and cdk9 C Simone et al incubated with GST-fusion proteins, GST-cdk9 or GSTMyoD, using GST as a negative control, for 2 h at 48C, rocking, for in vitro binding. These fusion proteins were precipitated by glutathione-agarose anity chromatography and the immunoprecipitates were washed extensively in CPA buer (20 mM Tris-HCl pH 7.6, 250 mM NaCl, 5 mM MgCl 2, 0.2 mM EDTA, 10% glycerol, 0.2% NP-40) containing fresh inhibitors and 1 mM DTT. Afterwards, the immunoprecipitates were resolved on 10% or 12% SDS ± PAGE and subjected to autoradiography. His-MyoDwt (125 ng), HisMyoD-Nter (125 ng), His-MyoD-bHLH (125 ng) and HisMyoD-Cter (125 ng) were incubated with eluted GST-cdk9 (50 ng) for 1 h at 48C, rocking, and pulled down with Hisbind resin (Novagen Inc.) The samples were then washed extensively in washing buer (CPA 30 mM imidazole) containing fresh inhibitors and 1 mM DTT. The samples were resolved on 10% SDS ± PAGE and subjected to immunoblot. Bacterially expressed His-MyoD was puri®ed and dialyzed (CPA buer 30 mM imidazole) and after 1 h 48C incubation with 35 S-IVT-cdk9 and/or -cycT2a His-bind resin was added (1 h 48C). The samples were washed extensively (CPA buer 30 mM imidazole), resolved on 8% SDS ± PAGE and subjected to autoradiography.
Western blot and immunoprecipitation (Ip)
C2C12-EGFP alone, C2C12-EGFP-cdk9 and C2C12-EGFPcdk9dn extracts (50 mg) were used for Western blot and C2C12 for Ips. These extracts were obtained by lysing the cells in Lysis Buer (50 mM Tris, 5 mM EDTA, 250 mM NaCl, 50 mM NaF, 0.1% Triton, 0.1 mM Na 3 VO 4 , and 10 mg/ml aprotinin, leupeptin and phenylmethylsulphonyl uoride (PMSF)). The protein concentration was determined by Bradford assay (Biorad, CA, USA), following the manufacturer's instructions and by using BSA as a standard. Immunoprecipitations were performed after preclearing the extracts with pre-immune rabbit serum. Anity puri®ed anticdk9 (1 : 50; De Falco et al., 2000) , anity puri®ed antiMyoD (1 : 20; Santa Cruz, CA) or anti-cycT2 (1 : 100; antibody incubations were performed overnight, at 48C, followed by the addition of protein A-sepharose for 60 min, rocking, at 48C. Beads were washed three times with Lysis Buer and twice with Lysis Buer 400 mM NaCl, and loading buer (50 mM Tris/HCl pH 6.8, 2% SDS, 10% glycerol) with or without 5% b-mercaptoethanol was added. The samples were resolved in 6, 8, 10 or 12% SDS ± PAAGels and were transferred to a Hybond-ECL nitrocellulose ®lter (Amersham Life Science Inc.) at 48C and at 70 V for 2 h. To ensure equal transferring, 0.5% Ponceau Red was used. The blots were blocked with TBST containing 5% nonfat dry milk. Anti-cdk9 (1 : 200), anti-MyoD (1 : 100), anticycT1 (1 : 1000; Peng et al., 1998 Peng et al., ), anti-cycT2 (1 : 2000 polyclonal antibody and anti-myogenin (1 : 100, , anti-MHC (1 : 100; , anti-b-tubulin (1 : 100; T-4026) monoclonal antibody were used in TBST containing 5% non-fat dry milk, according to the Western blot conditions suggested by Santa Cruz (Santa Cruz, CA, USA). Anti-rabbit and anti-mouse peroxidase conjugated (1 : 20000) (Amersham, IL, USA) and ECL detection system (NEN, Du Pont, MS, USA) were used for detection.
Transient transfections and luciferase assay
Transient transfections and luciferase assays were performed using kits according to the manufacturer's instructions (Lipofectamine, Life Technology, MD and Promega, WI, USA). Transfections were normalized by co-transfecting the bgal plasmid and by performing a standard b-galactosidase assay. Two mg of total DNA plasmid were transfected and transfection-luciferase assays were performed ®ve times in triplicate. There was no signi®cant dierence in the transfection eciencies among the various constructs as determined by the b-gal activity. No evidence of cdk9 altering the b-gal activity was observed. The expression of overexpressed proteins was controlled by Western blot analysis.
Kinase assay
Cell extracts (200 mg) prepared in Lysis Buer were used for immunoprecipitation with a polyclonal anti-cdk9, anti-cdk2 (1 : 40; De Luca et al., 1997b) and anti-cdk5 (1 : 40; Santa Cruz, CA) antibody (negative control: pre-immune rabbit serum). The immunocomplexes were pulled down with protein A-sepharose and washed three times with Lysis Buer and two times with Lysis Buer containing 400 mM NaCl. The complexes were also equilibrated in kinase assay buer (minus ATP) (20 mM HEPES pH 7.4, 10 mM Mg Acetate). The kinase assay was performed in a volume of 20 ml, using 5 mCi/sample of g-ATP (Amersham, IL, USA). Histidine-tagged MyoD wild-type and His-MyoDsp2 (between 0.1 and 1 mg) were added to the samples and incubated for 30 min at 308C. The reactions were stopped by adding 56Laemmli Buer and the samples were loaded and resolved on a 10% SDS ± PAGE.
Cyclohexamide treatment
NIH3T3 and 10T1/2 cells were transfected with 1 mg of CMV-MyoD and pcDNA3-cdk9-HA or pcDNA3-cdk9dn-HA in 100-mm-diameter dishes using kits according to the manufacturer's instructions (Lipofectamine, Life Technology, MD, USA and Promega, WI, USA). The cells were treated with cyclohexamide (Sigma, MO, USA) at 15 mg/ml for the indicated times and harvested for immunoblot analysis. MyoD was detected with anti-MyoD antibody. For each experiment b-tubulin was used as an internal control.
